|1.||Zhang, Xiang-Hua: 1 article (07/2013)|
|2.||Kim, Jeong-Oh: 1 article (07/2013)|
|3.||Oh, Ji-Eun: 1 article (07/2013)|
|4.||Kang, Jin-Hyoung: 1 article (07/2013)|
|5.||Shin, Jung-Young: 1 article (07/2013)|
|6.||Cheng, Ying: 1 article (07/2013)|
|7.||Zumstein-Mecker, S: 1 article (03/2001)|
|8.||Stephan, C: 1 article (03/2001)|
|9.||Fabbro, D: 1 article (03/2001)|
|10.||Fretz, H: 1 article (03/2001)|
03/21/2001 - "Like p16, the natural inhibitor of Cdk4, CINK4 inhibits Cdk4 activity in vitro and slows tumor growth in vivo. "
03/21/2001 - "CINK4 treatment resulted in statistically significantly (P: =.031) smaller mean tumor volumes in a mouse xenograft model. "
07/01/2013 - "We compared the anti-tumor efficacy of genetically knocked-down CDK4 and a pharmacological inhibitor of CDK4/6, CINK4, in KRAS mutation-positive lung adenocarcinoma cells. "
03/21/2001 - "Cell cycle effects of CINK4 on tumor and normal cells were studied by flow cytometry, and changes in phosphorylation of the retinoblastoma protein (pRb), a substrate of Cdk4, were determined by western blotting. "
07/01/2013 - "These data suggest CDK4 is a promising target for development of anti-cancer drugs and CINK4 combined with paclitaxel may be an effective therapeutic strategy for enhancing anti-tumor efficacy in KRAS mutation-positive lung adenocarcinoma. "
|1.||Adenocarcinoma of lung
|1.||Heterologous Transplantation (Xenotransplantation)